Changes in lactate dehydrogenase are associated with central gray matter lesions in newborns with hypoxic-ischemic

Sook Kyung Yum1, Cheong-Jun Moon1, Young-Ah Youn1

  • 1a Division of Neonatology , Department of Pediatrics, College of Medicine, The Catholic University of Korea , Seoul , Republic of Korea.

Insights

Changes in serum lactate dehydrogenase (LDH) can predict neurological outcomes in infants with hypoxic-ischemic encephalopathy (HIE). This study found that the percentage change in LDH levels was significantly higher in infants with brain lesions, suggesting LDH as a potential biomarker.

Area of Science:

  • Neonatal neurology
  • Biomarker discovery
  • Neuroimaging

Background:

  • Hypoxic-ischemic encephalopathy (HIE) poses a significant risk for neurological impairment in infants.
  • Predicting neurodevelopmental outcomes in HIE is crucial for timely intervention.
  • Brain magnetic resonance imaging (MRI) is a key tool for assessing HIE-related brain injury.

Purpose of the Study:

  • To evaluate the predictive value of serum lactate dehydrogenase (LDH) levels for neurological prognosis in infants with HIE.
  • To assess the relationship between LDH levels and brain MRI findings indicative of hypoxic-ischemic injury.
  • To determine if LDH can serve as a biomarker for neurodevelopmental outcomes.

Main Methods:

  • Retrospective review of medical records for infants diagnosed with HIE.
  • Measurement of serum LDH levels on day 1 (LDH1) and day 3 (LDH3) post-birth.
  • Analysis of brain MRI scans to identify hypoxic-ischemic lesions, particularly in the central gray matter.
  • Calculation of the percentage change in LDH (ΔLDH%) and its correlation with lesion presence.

Main Results:

  • Of 92 infants with HIE, 56.5% showed hypoxic-ischemic lesions on MRI, with 40.4% having central gray matter lesions.
  • The percentage change in serum LDH (ΔLDH%) was significantly higher in infants with central gray matter lesions compared to those without (36.9% vs. 6.6%, p=0.006).
  • Specific cutoffs for ΔLDH demonstrated good predictive values for identifying infants with central gray matter lesions, with a relative risk of 5.57 (p=0.001).

Conclusions:

  • Changes in serum LDH levels may serve as a valuable, non-invasive biomarker for predicting neurodevelopmental prognosis in infants with HIE.
  • Monitoring ΔLDH% could aid clinicians in identifying infants at higher risk of adverse neurological outcomes.
  • Further research is warranted to validate LDH as a prognostic tool in HIE.
Abstract